Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 plus anlotinib for previously treated metastatic colorectal cancer
ChiCTR2400079535Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and anlotinib in colorectal cancer (CRC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: progression-free survival. Started Jan 2024; status: recruiting.
02
Drugs
trifluridine + tipiracilanlotinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400079535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079535.